Stabilized EZH2 Peptides via Internal Cross-Linking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
EZH2 overexpression is linked to cancer development and maintenance, with existing methods struggling to effectively target and regulate its activity, particularly in cancer cells.
Innovation Solution
Development of structurally stabilized peptides that share sequence homology with EZH2, specifically internally cross-linked polypeptides that target and disrupt the EZH2/EED complex, reducing EZH2 protein levels and H3K27 trimethylation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing methods are used to target EZH2, then EZH2 activity can be regulated, but the effectiveness is insufficient particularly in cancer cells
Solution Approach 1:
The patent applies parameter changes by modifying the peptide structure through internal cross-linking, which changes the structural parameters of the peptide to enhance its binding affinity and stability. This resolves the contradiction by improving effectiveness through structural parameter optimization without requiring overly complex multi-component systems.
Solution Approach 2:
The patent creates composite peptide structures by combining multiple amino acid sequences with internal cross-links to form a stabilized polypeptide. This composite approach enhances the therapeutic effectiveness against EZH2 while maintaining a relatively simple single-molecule structure, thus resolving the contradiction between effectiveness and complexity.
2Reliability
If peptides are designed to bind EED and disrupt EZH2/EED complex, then EZH2 levels and H3K27 trimethylation are reduced, but peptide structural stability is insufficient
Solution Approach 1:
The patent applies preliminary action by pre-stabilizing the peptide structure through internal cross-linking before it encounters its target EED. This pre-formed stable structure ensures high binding affinity and sustained activity, resolving the contradiction by establishing structural stability in advance to support reliable binding function.
Solution Approach 2:
The internal cross-links act as intermediaries that mediate between the peptide sequence and its functional conformation. These cross-links stabilize the peptide structure without interfering with the binding interface, thus resolving the contradiction by providing structural support while preserving binding affinity.
3Reliability
If EZH2 is targeted to inhibit cancer cell proliferation, then cancer treatment efficacy is improved, but off-target effects may occur
Solution Approach 1:
The patent extracts and targets a specific functional interface (EED binding site) rather than attempting to inhibit EZH2 directly. By targeting the EED interaction, the peptide achieves cancer treatment efficacy while reducing off-target effects associated with direct EZH2 inhibition, thus resolving the contradiction through selective targeting.
Solution Approach 2:
The peptide is designed as a simplified copy or mimic of the natural EED-binding interface. This copied structure maintains the specific binding properties needed for effective cancer treatment while lacking the complex functions that could cause off-target effects, thus resolving the contradiction through selective functional replication.
Data Source
AI summary
Provided herein are polypeptides containing stabilized therapeutic peptides related to enhancer of zeste homolog 2 (EZH2), histone lysine N-methyltransferase. Also provided are compositions containing these polypeptides and methods of using such peptides in the treatment of cancer that include administering to a subject one of the polypeptides.